Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC

PHASE2RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
Prostate Cancer Metastatic Disease
Interventions
DRUG

Intense androgen deprivation therapy

Patients received ADT plus second-generation ARi (enzalutamide, apalutamide, darolutamide or rezvilutamide) for 2 years.

RADIATION

Radiation Therapy

Those allocated radiotherapy received 70Gy/2.8Gy/25f schedule for primary tumor and 70Gy/2.6-2.8Gy/25f or 37.5Gy/7.5Gy/5f for metastatic lymph nodes and bone lesions based on the size and location. Radiation should be finished within 2 years' systemic therapy.

PROCEDURE

radical prostatectomy

Those allocated surgery received robot-assisted laparoscopic radical prostaectomy plus extended pelvic lymph node dissection for local treatment. Surgery should be finished within 2 years' systemic therapy.

Trial Locations (1)

210008

RECRUITING

Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing

All Listed Sponsors
collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

Peking University First Hospital, Beijing, CHINA

UNKNOWN

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER